These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32075630)

  • 1. Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso.
    Nkwenkeu SF; Jalloh MF; Walldorf JA; Zoma RL; Tarbangdo F; Fall S; Hien S; Combassere R; Ky C; Kambou L; Diallo AO; Krishnaswamy A; Aké FH; Hatcher C; Patel JC; Medah I; Novak RT; Hyde TB; Soeters HM; Mirza I
    BMC Public Health; 2020 Feb; 20(1):254. PubMed ID: 32075630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.
    Aksnes BN; Walldorf JA; Nkwenkeu SF; Zoma RL; Mirza I; Tarbangdo F; Fall S; Hien S; Ky C; Kambou L; Diallo AO; Aké FH; Hatcher C; Patel JC; Novak RT; Hyde TB; Medah I; Soeters HM; Jalloh MF
    Vaccine; 2021 Oct; 39(43):6370-6377. PubMed ID: 34579975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso.
    Zoma RL; Walldorf JA; Tarbangdo F; Patel JC; Diallo AO; Nkwenkeu SF; Kambou L; Nikiema M; Ouedraogo A; Bationo AB; Ouili R; Badolo H; Sawadogo G; Krishnaswamy A; Hatcher C; Hyde TB; Aké F; Novak RT; Wannemuehler K; Mirza I; Medah I; Soeters HM
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S233-S243. PubMed ID: 31671442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign.
    Diallo AO; Soeters HM; Yameogo I; Sawadogo G; Aké F; Lingani C; Wang X; Bita A; Fall A; Sangaré L; Ouédraogo-Traoré R; Medah I; Bicaba B; Novak RT;
    PLoS One; 2017; 12(11):e0187466. PubMed ID: 29095907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018.
    Bwaka A; Bita A; Lingani C; Fernandez K; Durupt A; Mwenda JM; Mihigo R; Djingarey MH; Ronveaux O; Preziosi MP
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S140-S147. PubMed ID: 31671448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
    Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
    Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of missed opportunities for vaccination (MOV) in Burkina Faso using the World Health Organization's revised MOV strategy: Findings and strategic considerations to improve routine childhood immunization coverage.
    Kaboré L; Meda B; Médah I; Shendale S; Nic Lochlainn L; Sanderson C; Ouattara M; Kaboré WMF; Betsem E; Ogbuanu IU
    Vaccine; 2020 Nov; 38(48):7603-7611. PubMed ID: 33077298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
    Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
    PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization delivery in the second year of life in Ghana: the need for a multi-faceted approach.
    Nyaku M; Wardle M; Eng JV; Ametewee L; Bonsu G; Larbi Opare JK; Conklin L
    Pan Afr Med J; 2017; 27(Suppl 3):4. PubMed ID: 29296139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular insights into meningococcal carriage isolates from Burkina Faso 7 years after introduction of a serogroup A meningococcal conjugate vaccine.
    Topaz N; Kristiansen PA; Schmink S; Congo-Ouédraogo M; Kambiré D; Mbaeyi S; Paye M; Sanou M; Sangaré L; Ouédraogo R; Wang X
    Microb Genom; 2020 Dec; 6(12):. PubMed ID: 33332261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serogroup W Meningitis Outbreak at the Subdistrict Level, Burkina Faso, 2012.
    Cibrelus L; Medah I; Koussoubé D; Yélbeogo D; Fernandez K; Lingani C; Djingarey M; Hugonnet S
    Emerg Infect Dis; 2015 Nov; 21(11):2063-6. PubMed ID: 26488128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso.
    Vogel G
    Science; 2003 Mar; 299(5612):1499-501. PubMed ID: 12624241
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.
    Kristiansen PA; Ba AK; Ouédraogo AS; Sanou I; Ouédraogo R; Sangaré L; Diomandé F; Kandolo D; Saga IM; Misegades L; Clark TA; Préziosi MP; Caugant DA
    BMC Infect Dis; 2014 Dec; 14():663. PubMed ID: 25472422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.
    LaForce FM; Djingarey M; Viviani S; Preziosi MP
    Hum Vaccin Immunother; 2018 May; 14(5):1098-1102. PubMed ID: 28968148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.